Login / Signup

Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.

Yuji HosonoBrandon SieIago Pinal-FernandezKatherine PakChristopher A MecoliMaria Casal-DominguezBlake M WarnerMariana J KaplanJemima AlbaydaSonye DanoffThomas E LloydJulie J PaikEleni TiniakouRohit AggarwalChester V OddisSiamak Moghadam-KiaCarmelo Carmona-RiveraJose César MilisendaJosep Maria Grau-JunyentAlbert Selva O'CallaghanLisa Christopher-StineH Benjamin LarmanAndrew Lee Mammen
Published in: Annals of the rheumatic diseases (2022)
Anti-Sp4 autoantibodies appear to identify a subgroup of anti-TIF1γ-positive DM patients with lower cancer risk.
Keyphrases
  • systemic lupus erythematosus
  • transcription factor
  • disease activity
  • clinical trial
  • rheumatoid arthritis
  • metabolic syndrome
  • adipose tissue
  • dna binding
  • study protocol
  • phase iii